BR0311172A - Tratamento e prevenção de formação de cicatriz anormal em quelóides e outras lesões ou ferimentos internos ou cutâneos - Google Patents

Tratamento e prevenção de formação de cicatriz anormal em quelóides e outras lesões ou ferimentos internos ou cutâneos

Info

Publication number
BR0311172A
BR0311172A BR0311172-5A BR0311172A BR0311172A BR 0311172 A BR0311172 A BR 0311172A BR 0311172 A BR0311172 A BR 0311172A BR 0311172 A BR0311172 A BR 0311172A
Authority
BR
Brazil
Prior art keywords
pai
activity
keloids
abnormal
present
Prior art date
Application number
BR0311172-5A
Other languages
English (en)
Inventor
Tai-Lan Tuan
Paul D Benya
David Warburton
Original Assignee
Children S Hospital Los Angele
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children S Hospital Los Angele filed Critical Children S Hospital Los Angele
Publication of BR0311172A publication Critical patent/BR0311172A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"TRATAMENTO E PREVENçãO DE FORMAçãO DE CICATRIZ ANORMAL EM QUELóIDES E OUTRAS LESõES OU FERIMENTOS INTERNOS OU CUTâNEOS". A presente invenção refere-se a descobertas de que a redução da atividade de lnibidor -1 de Ativador de Plasminogênio (PAI-1) suprime uma deposição excessiva de colágeno que é conhecida como uma causa para a formação de cicatrizes anormais. Estas cicatrizes anormais incluem porém não estão limitadas a quelóides, adesões, cicatrizes hipertróficas, condições de desfiguração da pele, fibroses, condições fibrocísticas, contraturas, e escleroderma, todas as quais são associadas com ou causadas por um depósito excessivo de colágeno em um processo de cicatrizes de ferimento. Conseq³entemente, aspectos da presente invenção são direcionados à redução de atividade de PAI-1 para diminuir um acúmulo excessivo de colágeno. A atividade de PAI-1 pode ser reduzida por inibidores de PAI-1 que incluem porém não estão limitados aos anticorpos de neutralização de PAI-1, compostos com base em dicetopiperazina, compostos com base em ácido tetrâmico, Vitamina C, Vitamina E, Mifepristona (RU486) e Espironolactona para denominar alguns. Outro aspecto da presente invenção é direcionado a métodos de avaliar a atividade de PAI-1 em um processo de cicatrização de ferimento e determinação da propensão da formação de uma cicatriz anormal.
BR0311172-5A 2002-05-13 2003-05-13 Tratamento e prevenção de formação de cicatriz anormal em quelóides e outras lesões ou ferimentos internos ou cutâneos BR0311172A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38069602P 2002-05-13 2002-05-13
PCT/US2003/015548 WO2004041155A2 (en) 2002-05-13 2003-05-13 Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions

Publications (1)

Publication Number Publication Date
BR0311172A true BR0311172A (pt) 2005-04-26

Family

ID=32312400

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311172-5A BR0311172A (pt) 2002-05-13 2003-05-13 Tratamento e prevenção de formação de cicatriz anormal em quelóides e outras lesões ou ferimentos internos ou cutâneos

Country Status (7)

Country Link
US (1) US20040043026A1 (pt)
EP (1) EP1509236A4 (pt)
JP (1) JP2006507297A (pt)
CN (1) CN1668312A (pt)
AU (1) AU2003301809A1 (pt)
BR (1) BR0311172A (pt)
WO (1) WO2004041155A2 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2254645A1 (en) * 1998-11-23 2000-05-23 Pulmonox Medical Corporation Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
US7516742B2 (en) * 1999-11-24 2009-04-14 Cardinal Health 207, Inc. Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing
US7122018B2 (en) * 2000-12-26 2006-10-17 Sensormedics Corporation Device and method for treatment of wounds with nitric oxide
US6432077B1 (en) * 2000-12-26 2002-08-13 Sensormedics Corporation Device and method for treatment of surface infections with nitric oxide
US7531133B2 (en) * 2002-09-10 2009-05-12 Pulmonox Technologies Corporation Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma
US20050170445A1 (en) * 2004-01-07 2005-08-04 Duke University Methods of establishing profiles for use in evaluating wound healing and biocompatibility of implant materials and microarrays useful therefor
US20050186261A1 (en) * 2004-01-30 2005-08-25 Angiotech International Ag Compositions and methods for treating contracture
US8518457B2 (en) * 2004-05-11 2013-08-27 Pulmonox Technologies Corporation Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
MXPA06013111A (es) 2004-05-11 2007-05-23 Sensormedics Corp Dosificacion intermitente de gas de oxido nitrico.
US20070154570A1 (en) * 2004-09-29 2007-07-05 Miller Christopher C Use of nitric oxide in the treatment and disinfection of biofilms
US8043619B2 (en) * 2004-10-08 2011-10-25 Yaron Ilan Methods and uses of leptin in immune modulation
GB2420281A (en) * 2004-11-22 2006-05-24 Stegram Pharmaceuticals Ltd Topical formulations for use in the treatment or prevention of dermatological conditions
WO2007013078A2 (en) * 2005-07-27 2007-02-01 Mor Research Applications Ltd. Inhibition of the renin-angiotensin system for the treatment of renal, vascular and cartilage pathology
GT200600411A (es) * 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
AU2006294581B2 (en) * 2005-09-27 2011-11-03 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US20070116785A1 (en) * 2005-11-18 2007-05-24 Miller Christopher C Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US8079998B2 (en) * 2006-10-20 2011-12-20 Pulmonox Technologies Corporation Methods and devices for the delivery of therapeutic gases including nitric oxide
US20080193566A1 (en) * 2007-02-09 2008-08-14 Miller Christopher C Use of high dose concentrations of gaseous nitric oxide
WO2008138350A1 (en) * 2007-05-14 2008-11-20 Sygehuset Glostrup Prevention of intraocular fibrosis
US8802073B2 (en) * 2007-11-15 2014-08-12 Prelief Inc. Methods and compositions for wound healing
WO2009089059A2 (en) * 2008-01-09 2009-07-16 Intrexon Corporation Therapeutic inhibitors of pai-1 function methods of their use
EP2582365B1 (en) 2010-06-16 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for stimulating reepithelialisation during wound healing
CN102335167A (zh) * 2010-07-28 2012-02-01 中国医学科学院整形外科医院 卡托普利在抑制瘢痕增生中的应用
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
US8877185B2 (en) 2012-05-10 2014-11-04 Stan S. Sastry Managing and treating keloids
CN112142845A (zh) * 2013-08-13 2020-12-29 赛诺菲 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途
JP6512213B2 (ja) * 2014-02-21 2019-05-15 アステラス製薬株式会社 新規抗ヒトｐａｉ−１抗体
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
WO2016138025A2 (en) 2015-02-23 2016-09-01 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
WO2016141182A1 (en) 2015-03-03 2016-09-09 Yee Richard W Compositions and methods for treating ocular diseases
CN107847526A (zh) 2015-05-20 2018-03-27 组织技术公司 用于预防上皮细胞的增殖和上皮‑间充质转换的组合物和方法
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
ES2969021T3 (es) 2016-04-08 2024-05-16 Cereno Scient Ab Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de las mismas
KR102487144B1 (ko) 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 큰 물질의 경피 전달
CA3047181A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Method and drug for preventing and treating obesity
EP3556389A4 (en) * 2016-12-15 2020-07-15 Talengen International Limited METHOD FOR PREVENTING AND TREATING HEPATIC FIBROSIS
CN108210906A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 治疗冠状动脉粥样硬化及其并发症的药物及其用途
CA3047170A1 (en) * 2016-12-15 2018-06-21 Talengen International Limited Method for preventing and treating drug-induced renal injury
CN110366425A (zh) 2016-12-15 2019-10-22 泰伦基国际有限公司 一种预防动脉粥样硬化及其并发症的方法
WO2018145147A1 (en) * 2017-02-07 2018-08-16 David Chin A method of treating a fibrotic condition associated with excessive collagen formation using activators of the collagenase production pathway.
CN111344004A (zh) 2017-06-19 2020-06-26 泰伦基国际有限公司 一种调控glp-1/glp-1r 的方法和药物
CN107648611A (zh) * 2017-09-18 2018-02-02 浙江大学 复方血管紧张素转换酶类抗瘢痕外用制剂
CN107617107A (zh) * 2017-09-18 2018-01-23 浙江大学 一种复方血管紧张素转换酶类抗瘢痕制剂
WO2020056191A1 (en) * 2018-09-13 2020-03-19 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
WO2020056160A1 (en) * 2018-09-13 2020-03-19 Eirion Therapeutics, Inc. Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor
US20220340665A1 (en) 2019-09-30 2022-10-27 Renascience Inc. Inhibitor against expression of immune checkpoint molecule
US20220401416A1 (en) * 2021-06-22 2022-12-22 Buderer Drug Company Angiotensin receptor blockers for treatment of fibrotic disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
IL112627A0 (en) * 1994-02-14 1995-05-26 Xenova Ltd Diketopiperazines, their preparation and pharmaceutical or veterinary compositions containing them
US5891877A (en) * 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds

Also Published As

Publication number Publication date
WO2004041155A3 (en) 2004-09-23
WO2004041155A2 (en) 2004-05-21
EP1509236A4 (en) 2008-07-30
AU2003301809A1 (en) 2004-06-07
CN1668312A (zh) 2005-09-14
US20040043026A1 (en) 2004-03-04
EP1509236A2 (en) 2005-03-02
JP2006507297A (ja) 2006-03-02
AU2003301809A8 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
BR0311172A (pt) Tratamento e prevenção de formação de cicatriz anormal em quelóides e outras lesões ou ferimentos internos ou cutâneos
Relhan et al. Management of chronic paronychia
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
IL169258A0 (en) Methods of detecting the inhibition of fibrocyte formation and methods and compositions for enhancing fibrocyte formation
ATE459349T1 (de) Verfahren zur behandlung von nagelpilz und anderen mikrobiellen und mykotischen erkrankungen und dafür geeignete zusammensetzungen
WO2005091991A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
EP2266561A3 (en) IKK Inhibitors for the Treatment of Endometriosis
ECSP066362A (es) Inhibidores de quinesina mitótica.
WO2005000213A8 (en) Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors
SE0301886D0 (sv) New use V
BR0304601A (pt) Curativo de ferimento hemostático contendo polissacarìdeos modificados por aldeìdo
BR0318498A (pt) composições terapêuticas à base de porìfero para o tratamento e a prevenção de doenças da pele
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
SE0301882D0 (sv) New use I
WO2006037029A3 (en) Methods for treating conditions associated with the accumulation of excess extracellular matrix
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
BR9914735A (pt) Processo para tratamento de sépsia
ATE430572T1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
AR040303A1 (es) Vendaje para heridas que contiene un polisacarido regenerado modificado con aldehido
Choo et al. The clinical efficacy of early intervention for infected preauricular sinus
DK1231910T3 (da) Pentamidin til behandling af cancer
Ortiz et al. Laser therapy for Hailey-Hailey disease: review of the literature and a case report
BR9910678A (pt) Composto, composição farmacêutica, método para traramento ou prevenção de uma doença inflamatória, método para tratamento de uma condição ou uma doença mediada por mmps, tnf, agrecanase, ou um composto dos mesmos, em um mamìfero, método de redução de nìveis de tnf em pacientes, sem a inibição de mmps, método para tratamento de uma condição ou uma doença e uso de um novo composto
DE60334556D1 (de) Chorionic gonadotropin zur Behandlung des chronischen Schmerzsyndroms des Beckens
BR0213126A (pt) Compostos heterocìclicos insaturados de 6 membros úteis para inibição seletiva da cascata de coagulação

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/401 (2006.01), A61K 31/355 (2006.01), A61K